Summary (tl;dr)

Marty Makary has resigned as the Commissioner of the U.S. Food and Drug Administration (FDA) after a contentious 13-month term, and Kyle Diamantas, the agency's Deputy Commissioner for Food, has been named acting commissioner.

Essential Background

Dr. Marty Makary, a surgical oncologist and professor from Johns Hopkins University, was appointed as the 27th FDA Commissioner in March 2025, receiving bipartisan support from the U.S. Senate. During his tenure, Makary focused on modernizing the agency, enhancing consumer protection, and accelerating the availability of new treatments and cures. He also gained public attention for his critical views on COVID-19 related public health measures, including pediatric mask and vaccine mandates.

The Full Story

Marty Makary officially resigned from his position as FDA Commissioner on May 12, 2026, following mounting pressure and internal conflicts with the White House and Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.. This rapid departure, marking one of the shortest tenures for an FDA commissioner in recent history, was preceded by weeks of speculation about his removal due to various controversial decisions and policy disagreements. Key issues contributing to the friction included the FDA's handling of drug approvals, particularly for rare-disease treatments, its oversight of vaccines, and its authorization of flavored vaping products, a matter that reportedly drew criticism from President Donald Trump. Makary also faced backlash from anti-abortion organizations over allegations that he was delaying a safety review of the abortion pill mifepristone. Kyle Diamantas, who previously served as the FDA's Deputy Commissioner for Food, overseeing the Human Foods Program, has been appointed as the acting commissioner.

Why It Matters

Makary's resignation and the immediate appointment of Kyle Diamantas as acting commissioner signify a pivotal leadership change within the FDA during a sensitive period for federal health policy, impacting pharmaceutical companies, public health organizations, and consumers across the nation. This transition occurs amidst ongoing debates regarding regulatory strategies for drug approvals, vaccine policies, and consumer product regulations, such as those for flavored e-cigarettes. With his legal and food policy background, Diamantas is expected to navigate the agency through this interim period as the White House seeks a permanent commissioner, potentially recalibrating interagency relationships given his prior role as a liaison with HHS and the White House. His leadership will be crucial in setting the FDA's strategic direction for food safety and nutrition, as well as its approach to various public health challenges and regulatory enforcement.

Geographic Location

• Washington, D.C., District of Columbia, United States (Marty Makary's resignation as FDA Commissioner; White House and HHS involved in the decision-making process for FDA leadership)
• Gainesville, Alachua County, Florida, United States (Kyle Diamantas earned his Juris Doctor from the University of Florida Levin College of Law)
• Orlando, Orange County, Florida, United States (Kyle Diamantas earned his Bachelor's degree in political science from the University of Central Florida)
• Miami, Miami-Dade County, Florida, United States (Kyle Diamantas previously a Partner at Jones Day advising FDA-regulated industry clients)